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The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia
To the Editor: The article by Zeisler and col-
leagues (Jan. 7 issue)1 showed that a ratio of sol-
uble fms-like tyrosine kinase 1 (sFlt-1) to placental 
growth factor (PlGF) of 38 or lower ruled out 
preeclampsia with a negative predictive value of 
99.3% within 1 week in women with clinical sus-
picion of it. Critical in this study are the inclusion 
criteria used to define “impending” preeclampsia. 
In medicine, a definition of suspected preeclamp-
sia is lacking, and the inclusion of patients at low 
risk may artificially increase the negative predic-
tive value of a test by diluting the weight of false 
negative events. Only 41.5% of the women in the 
validation cohort had new-onset hypertension or 
an exacerbation of preexisting hypertension. Oth-
er clinical symptoms considered as inclusion cri-
teria are often described in women with overt 
preeclampsia and used to define its severity, but 
in the absence of an elevated blood pressure, they 
lose their clinical importance. We wonder wheth-
er the simple inclusion of blood pressure instead 
of the angiogenic ratio in the evaluation of symp-
tomatic patients would have yielded the same 
figure for the negative predictive value.
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The authors reply: In PROGNOSIS (Prediction 
of Short-Term Outcome in Pregnant Women with 
Suspected Preeclampsia Study), pregnant women 
were enrolled on the basis of signs and symptoms 
of preeclampsia or the HELLP syndrome (charac-
terized by hemolysis, elevated liver-enzyme levels, 
and low platelet counts), including high blood 
pressure, as described in clinical guidelines.1,2 
The prevalence of preeclampsia in our cohort was 
19.0%, as compared with 2 to 5% among all 
pregnant women (indicating that women with a 
high risk of preeclampsia were included in the 
study). Blood pressure is limited in predicting ad-
verse pregnancy outcomes (e.g., the HELLP syn-
drome and eclampsia).3 Importantly, up to 20% 
of cases of the HELLP syndrome develop in wom-
en without previous onset of hypertension.4
The area under the curve in the receiver-oper-
ating-characteristic analysis for prediction of pre-
eclampsia or the HELLP syndrome within 1 week 
was 0.884 (95% confidence interval [CI], 0.837 
to 0.932) for the sFlt-1:PlGF ratio, as compared 
with 0.715 (95% CI, 0.650 to 0.780) for systolic 
and diastolic blood pressure in the full PROGNOSIS 
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data set. As we noted in the article, a post hoc 
analysis suggested that the addition of the sFlt-
1:PlGF ratio to blood-pressure and proteinuria 
assessments improved the prediction of preeclamp-
sia over these other measures alone.
Harald Zeisler, M.D.
Medical University Vienna 
Vienna, Austria
Martin Hund, Ph.D.
Roche Diagnostics International 
Rotkreuz, Switzerland
Stefan Verlohren, M.D., Ph.D.
Charité University Medicine 
Berlin, Germany 
stefan . verlohren@ charite . de
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
1. American College of Obstetricians and Gynecologists’ Task 
Force on Hypertension in Pregnancy. Hypertension in pregnan-
cy: report of the American College of Obstetricians and Gyne-
cologists Obstet Gynecol 2013; 122: 1122-31.
2. Tranquilli AL, Dekker G, Magee L, et al. The classification, 
diagnosis and management of the hypertensive disorders of 
pregnancy: a revised statement from the ISSHP. Pregnancy Hy-
pertens 2014; 4: 97-104.
3. Sibai BM, Stella CL. Diagnosis and management of atypical 
preeclampsia-eclampsia. Am J Obstet Gynecol 2009; 200(5): 481.
e1-7.
4. Sibai BM. Diagnosis, controversies, and management of the 
syndrome of hemolysis, elevated liver enzymes, and low platelet 
count. Obstet Gynecol 2004; 103: 981-91.
DOI: 10.1056/NEJMc1602338
Azithromycin versus Doxycycline for Chlamydia
To the Editor: Within the community of pro-
viders who treat sexually transmitted infections, 
there has been concern that azithromycin may be 
less effective than doxycycline in treating Chla-
mydia trachomatis infection. Geisler et al. (Dec. 24 
issue)1 report on their trial comparing these two 
drugs, and in an accompanying editorial, Quinn 
and Gaydos2 discuss the problem of treatment 
for these genital tract infections. Yet, neither the 
article nor the editorial mentions the treatment 
of extragenital infections. Such infections are 
not rare. Testing men who have sex with men for 
rectal and oropharyngeal C. trachomatis infection, 
as compared with testing for urethral infection 
alone, doubles the number of men who are found 
to have C. trachomatis infection.3 Such infections 
are also common in women, although with ad-
ditional testing for rectal and oropharyngeal in-
fection, the increment is less.4
Many anecdotal reports have indicated that 
azithromycin is less effective than doxycycline 
for the treatment of rectal, oropharyngeal, or 
genital infection. For example, in a retrospec-
tive cohort study, 23 of 136 men (17%) tested 
positive for chlamydia infection 14 to 60 days 
after treatment with azithromycin, and 0 of 36 
men tested positive 14 to 60 days after treat-
ment with doxycycline.5 These studies were sug-
gestive, not conclusive. The biologic features of 
C. trachomatis infection and antibiotic levels may 
vary according to the anatomical site of infec-
tion. Data from trials of treatment of extrageni-
tal C. trachomatis infection as well as from trials 
of treatment of genital C. trachomatis infection are 
lacking.
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To the Editor: Geisler et al. do not establish the 
noninferiority of azithromycin to doxycycline for 
the treatment of urogenital C. trachomatis infection. 
Both drugs are currently recommended as first-line 
options for C. trachomatis infections (genotypes D 
through K).1,2
In the trial reported by Geisler and colleagues, 
4 of the 5 patients with treatment failure in the 
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